ZURICH (Reuters) – Novartis has signed an option, cooperation and license agreement with BeiGene Ltd for the cancer therapy Ociperlimab (BGB-A1217) in order to expand its activities in immuno-oncology, the Swiss drug manufacturer announced on Monday Under the terms of the agreement, Novartis will pay BeiGene an upfront payment of $ 300 million and a fee of up to $ 700 million if the option for Ociperlimab is exercised before the end of 2023, which is currently in two Phase III lung cancer studies and other studies are being evaluated in a wide variety of solid tumors.
Similar title :
– BeiGene expands collaboration with Novartis to develop and commercialize the TIGIT inhibitor BeiGene& # 39 …
– BeiGene receives up to US $ 1 billion in oncology deal with Novartis
– <a href =" /? S = Novartis cancer therapy options As part of a $ 1 billion deal
– BeiGene (BGNE) expands collaboration with Novartis (NVS) to develop and commercialize BeiGene& # 39’s TIGIT inhibitor …
Keywords:
